Arca
Skip to content

Post-traumatic stress disorder

Drug research and approvals for post-traumatic stress disorder: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 400 studies of post-traumatic stress disorder are recruiting on ClinicalTrials.gov, and Health Canada has authorized 25 drug trials for it since 2013.

  • Recruiting worldwide: 400
  • Trials authorized in Canada: 25
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 400 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 25; search them all in Canada trials
Jun 17, 2026A phase 2b/3, multicentre, randomised, double-blind, controlled trial, with an open label extension, to investigate the efficacy, safety, and tolerability of…COMP360 (PSILOCYBIN)COMPASS PATHFINDER LIMITEDOngoing
Jun 8, 2026Psilocybin-assisted therapy for post-traumatic stress disorder in survivors of intimate partner violence.PSILOCYBIN (PEX010)GOVERNORS OF THE UNIVERSITY OF CALGARYOngoing
Jul 14, 2025Ketamine assisted psychotherapy to improve quality of life in veterans and civilians with comorbid chronic pain and posttraumatic stress disorder: an…KETAMINEDR. YULIYA KNYAHNYTSKAOngoing
Feb 5, 2024A multi-site phase 3 study of the efficacy of mdma-assisted psychotherapy for the treatment post-traumatic stress disorder in veterans and front-line workersMETHYLENEDIOXYMETHAMPHETAMINE (MDMA)ATMA JOURNEY CENTRESPending
Jul 26, 2023Psilocybin-assisted massed cognitive processing therapy for chronic posttraumatic stress disorder: an open-label trialPSILOCYBINST. MICHAEL'S HOSPITAL UNITY HEALTH TORONTOOngoing
Apr 14, 2023A randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and efficacy of psilocybin-assisted psychotherapy in treating severe…PSILOCYBIN (APEX-002-A02)APEX LABS LTDPending
Mar 10, 2023Stellate ganglion block in the treatment of posttraumatic stress disorder: outcome evaluation, mechanism of action, and integration in care ¿ a phase III…BUPIVACAINEUNIVERSITY OF OTTAWA INSTITUTE OF MENTAL HEALTH RESEARCHOngoing
Jan 4, 2023A randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of psilocybin capsule in treating moderate depression…PSILOCYBIN (APEX-002-B01)APEX LABS INC.Pending
Aug 3, 2022Psilocybin assisted therapy for anxiety and mood disorders: a transdiagnostic open label clinical trial for improving well-being (pam-well)PSILOCYBINBRAIN AND COGNITION DISCOVERY FOUNDATIONClosed
Jul 7, 2022Standard vs. modified reconsolidation interventions for public safety personnel diagnosed with post-traumatic stress disorder: a proposed pilot studyPROPRANOLOLDOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTEPending

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.